Acknowledgement
This study was performed using HIRA-NPS 2011-2020 S20220518007), but the results of this study have no concern with the Ministry of Health and Welfare and HIRA.
References
- Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999;12(2):310-50. https://doi.org/10.1128/CMR.12.2.310
- Khan AAH, Karuppayil SM. Fungal pollution of indoor environments and its management. Saudi J Biol Sci 2012;19(4):405-26. https://doi.org/10.1016/j.sjbs.2012.06.002
- Seyedmousavi S, Guillot J, Arne P, et al. Aspergillus and aspergilloses in wild and domestic animals: a global health concern with parallels to human disease. Med Mycol 2015;53(8):765-97. https://doi.org/10.1093/mmy/myv067
- Bongomin F, Gago S, Oladele RO, Denning DW. Global and multinational prevalence of fungal diseases-estimate precision. J Fungi (Basel) 2017;3(4):57.
- Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;63(4):e1-60. https://doi.org/10.1093/cid/ciw326
- Husain S, Camargo JF. Invasive Aspergillosis in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33(9):e13544.
- Tudesq JJ, Peyrony O, Lemiale V, Azoulay E. Invasive pulmonary aspergillosis in nonimmunocompromised hosts. Semin Respir Crit Care Med 2019;40(4):540-7. https://doi.org/10.1055/s-0039-1696968
- Jenks JD, Hoenigl M. Treatment of aspergillosis. J Fungi (Basel) 2018;4(3):98.
- Ullmann AJ, Aquado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018;24 Suppl 1:e1-38. https://doi.org/10.1016/j.cmi.2018.01.002
- Tutar N, Metan G, Koc AN, et al. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Multidiscip Respir Med 2013;8(1):59.
- Vallabhaneni S, Benedict K, Derado G, Mody RK. Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000-2013 external icon. Open Forum Infect Dis 2017;4(1):ofw268.
- National Health Insurance Service. Annual report on health insurance statistics. Available from https://www.nhis.or.kr/nhis/together/wbhaec06300m01.do. Accessed June 8, 2023.
- Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health 2014;36:e2014008.
- Healthcare Bigdata Hub. Patient sample data guide. Available from https://opendata.hira.or.kr/op/opc/selectPatDataAplInfoView.do. Accessed June 10, 2022
- Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016;47(1):45-68. https://doi.org/10.1183/13993003.00583-2015
- DATA.GO.KR. HIRA_Drug Price Master_Medicine Main Ingredient. Available from https://www.health.kr/drug_info/basedrug/main_ingredient.html. Accessed June 10, 2022.
- Tarka P, Nitsch-Osuch A, Gorynski P, Tyszko P, Bogdan M, Kanecki K. Epidemiology of pulmonary aspergillosis in hospitalized patients in Poland during 2009-2016. Adv Exp Med Biol 2019;1160:73-80. https://doi.org/10.1007/5584_2019_347
- Maitre T, Cottenet J, Godet C, et al. Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis. Eur Respir J 2021;58(2):2003345.
- KOSIS. Status of hospitals by national region. Available from https://kosis.kr/statHtml/statHtml.do?orgId=354&tblId=DT_MIRE01. Accessed August 10, 2022.
- Ledoux MP, Guffroy B, Nivoix Y, Simand C, Herbrecht R. Invasive Pulmonary Aspergillosis. Semin Respir Crit Care Med 2020;41(1):80-98. https://doi.org/10.1055/s-0039-3401990
- Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15. https://doi.org/10.1056/NEJMoa020191
- Herbrecht R, Patterson TF, Slavin MA, et al. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis 2015;60(5):713-20. https://doi.org/10.1093/cid/ciu911
- Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34(5):563-71. https://doi.org/10.1086/324620
- Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97(2):135-44. https://doi.org/10.1016/0002-9343(94)90023-X
- Health Insurance Review and Assessment Service. Drug benefit list. Available from https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014050000&brdScnBltNo=4&brdBltNo=1623. Accessed August 10, 2022.